Get the Stockscreener App
2.80
3.13%
+0.085
After Hours:
2.80
Aytu BioPharma Inc stock is currently priced at $2.80, with a 24-hour trading volume of 13,960.
It has seen a +3.13% increased in the last 24 hours and a -7.89% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.76 pivot point. If it approaches the $2.80 resistance level, significant changes may occur.
Previous Close:
$2.715
Open:
$2.8
24h Volume:
13,960
Market Cap:
$15.59M
Revenue:
$98.50M
Net Income/Loss:
$-18.00M
P/E Ratio:
-0.2726
EPS:
-10.27
Net Cash Flow:
$6.11M
1W Performance:
-2.55%
1M Performance:
-7.89%
6M Performance:
+6.87%
1Y Performance:
+4.09%
1D Range:
$2.63
$2.80
52W Range:
$1.38
$3.50
Aytu BioPharma Inc Stock (AYTU) Company Profile
Name
Aytu BioPharma Inc
Sector
Phone
720 437 6580
Address
373 Inverness Parkway, Suite 206, Englewood
Aytu BioPharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu BioPharma Inc Stock (AYTU) Latest News
Aytu BioPharma Inc Stock (AYTU) Financials Data
Aytu BioPharma Inc (AYTU) Revenue 2024
AYTU reported a revenue (TTM) of $98.50 million for the quarter ending December 31, 2023, a -6.71% decline year-over-year.
Aytu BioPharma Inc (AYTU) Net Income 2024
AYTU net income (TTM) was -$18.00 million for the quarter ending December 31, 2023, a +76.56% increase year-over-year.
Aytu BioPharma Inc (AYTU) Cash Flow 2024
AYTU recorded a free cash flow (TTM) of $6.11 million for the quarter ending December 31, 2023, a +121.99% increase year-over-year.
Aytu BioPharma Inc (AYTU) Earnings per Share 2024
AYTU earnings per share (TTM) was -$4.04 for the quarter ending December 31, 2023, a +91.61% growth year-over-year.
About Aytu BioPharma Inc
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
1.11%
1.67%
Cap:
|
Volume (24h):